2023 was a troublesome calendar year for that biopharma market, with a number of corporations downsizing and restructuring their workforces to remain afloat. You can find signs of recovery, as mergers and acquisitions picked up across the pharmaceutical and existence sciences sector while in the latter Component of 2023 and https://sites.google.com/view/bio-sites/blog